FDA Gives Go-Ahead to Second Paclitaxel-Eluting Stent for Small-Diameter Coronaries

June 03, 2009

June 3, 2009 (Natick, Massachusetts)— The FDA has given Boston Scientific the marketing go-ahead for its Taxus Liberté Atom coronary stent system for use in vessels as narrow as 2.25 mm in diameter, according to a company statement [1].

The paclitaxel-eluting device becomes the second drug-eluting stent (DES) to be approved in the US for coronary segments that small, the company said. Its own Taxus Express Atom stent was approved for small vessels in September of last year.

Design improvements in the Liberté small-vessel DES compared with the Express small-vessel DES include, according to the company, "thinner struts to allow better stent deliverability and conformability, as well as uniform stent geometry for consistent lesion coverage and drug distribution."

Investigators reported at TCT 2007 that the nine-month rate of target-vessel revascularization was 58% lower among patients who received a Liberté compared with those who got an Express in the 261-patient TAXUS ATLAS Small Vessel Trial [2].


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.